Fig. 3.
Dose-adjustment map and correlation between etoposide DI and age.
(A) Map of dose levels achieved, according to cycle, for each patient. The percentage of cycles administered at each dose level is shown at right. Overall, 56% of cycles had escalation above and 5% had reduction below the starting-dose level. (B) Correlation between etoposide DI and age (r = −0.48;P2 = .0004) shows that older patients could not tolerate as high a dose rate as younger patients, possibly because of decreased hematopoietic tolerance or altered pharmacokinetics.
